血浆置换对肥胖青少年患者依诺肝素抗Xa活性的影响
本文报道一名13岁肥胖女孩(92 kg)因肺栓塞接受依诺肝素治疗,同时因疑似自身免疫性脑炎接受血浆置换。在最后两次血浆置换期间监测抗Xa活性,发现血浆置换后抗Xa活性下降速率显著增加(0.28 IU/mL/小时 vs 0.088 IU/mL/小时),需调整依诺肝素剂量以维持治疗范围。提示血浆置换可显著改变依诺肝素抗凝效果,建议密切监测抗Xa水平。
要点
- 血浆置换可加速依诺肝素抗Xa活性下降,下降速率相差3倍以上。
- 血浆置换期间需增加依诺肝素剂量,停用后需减量以避免出血风险。
- 建议同时使用依诺肝素和血浆置换时密切监测抗Xa水平。
核心结论
- 血浆置换可显著降低肥胖青少年患者依诺肝素的抗Xa活性,可能降低抗凝效果并增加停用后出血风险。
研究设计与样本
- 病例报告:一名13岁肥胖女孩(92 kg),因肺栓塞接受依诺肝素治疗,同时因疑似自身免疫性脑炎接受血浆置换。
主要发现
- 血浆置换期间抗Xa活性下降速率为0.28 IU/mL/小时,无血浆置换日为0.088 IU/mL/小时,差异大于3倍。
- 维持抗Xa活性在0.5-1 IU/mL治疗范围内所需依诺肝素剂量:血浆置换期间为0.98 mg/kg/次,无血浆置换时为0.69 mg/kg/次。
关键数值与推荐
- 抗Xa活性治疗范围设定为0.5-1 IU/mL。
临床怎么用
- 同时使用依诺肝素和血浆置换时,建议密切监测抗Xa水平。
- 开始血浆置换时可能需要增加依诺肝素剂量,停用时可能需要减少剂量。
局限性
- 单例病例报告,结果需在更多患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To our knowledge, the effect of plasmapheresis on the anti-factor Xa activity of enoxaparin has never been reported. We describe a 13-year-old, obese (92-kg) girl who was treated with enoxaparin for a pulmonary embolism while receiving plasmapheresis for suspected autoimmune encephalitis and who experienced clinically significant reductions in anti-factor Xa activity after plasmapheresis. She received five courses of plasmapheresis, with the final two administered during treatment with enoxaparin. Her anti-factor Xa concentrations were highly variable, and we hypothesized that plasmapheresis was affecting these levels. To test this hypothesis, anti-factor Xa concentrations were measured before and immediately after the patient's last plasmapheresis treatment, and then again 2 days after plasmapheresis. The rate of anti-factor Xa activity decline was 0.28 IU/mL/hour with plasmapheresis and only 0.088 IU/mL/hour on the day without plasmapheresis, representing a greater than 3-fold difference. The changes in anti-factor Xa activity due to plasmapheresis altered the final enoxaparin dosage required to remain in the therapeutic range of 0.5-1 IU/mL (0.98 mg/kg/dose while receiving plasmapheresis vs 0.69 mg/kg/dose without plasmapheresis). Our patient's data suggest that plasmapheresis can significantly alter enoxaparin's anticoagulant effect as measured by anti-factor Xa concentrations, which could cause a decreased anticoagulant effect during plasmapheresis and an increased risk of bleeding on plasmapheresis discontinuation. If concurrent enoxaparin-based anticoagulation and plasmapheresis are necessary, close monitoring of anti-factor Xa levels is advisable. Dose escalations and reductions of enoxaparin may be necessary when initiating and discontinuing plasmapheresis, respectively.
引用
- Rahawi KW, Higgins KL, Noda C, et al. Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient. Pharmacotherapy. 2017. PMID: 28152224. doi:10.1002/phar.1907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。